A company called GB Sciences announced the filing of a patent for the treatment of chronic pain based on myrcene-containing complex mixtures (“MCCM”).
The company states that its chronic pain formulations are substantially free of delta-9 tetrahydrocannabinol (“THC”), which minimizes their potential for abuse.
It’s a long way from a patent application to clinical trials and any data showing efficacy or safety of treatments for chronic pain.
“Our current drug discovery efforts were accelerated through the combination of proprietary in silico prediction approach, high-throughput screening techniques using cell-based models,” the company stated in a press release. “The current provisional patent application covers myrcene-containing complex mixtures capable of targeting the non-traditional cannabinoid receptor, TRPV1. Our latest patent application complements the issued TRPV1 patent that GB Sciences licensed from Makai Biotechnology in December of 2016,” the release further stated.
“Many cannabis researchers have theorized that the role of terpenes in cannabis-based therapies is to act as so-called ‘Entourage’ components. We show that the TRPV1 receptor is a target for these ‘Entourage’ compounds, a molecular interaction that had previously been demonstrated for several of the cannabinoids,” said Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences, Inc.
“We have demonstrated that beta-myrcene is the most significant of several terpenes derived from the cannabis plant that are capable of activating the TRPV1 receptor. Myrcene, like capsaicin, causes TRPV1 desensitization after prolonged exposure, and should therefore prove useful in treating chronic pain. In creating our novel MCCM mixtures for pain, we have also demonstrated that other terpenes and cannabinoids present in the complex mixture, including those that do not demonstrate significant TRPV1 agonist activity on their own, act in combination to increase the efficacy of myrcene. Unlike other pain medications, we leverage molecular synergies among cannabis-plant compounds to target multiple receptors within pain-sensing neural bundles to increase their combined effectiveness at pain relief.”
“These new chronic pain and heart formulas adhere to GB Science’s strategy of commercializing complex mixtures of cannabis-derived compounds whose pharmaceutical activity does not require THC. Instead, the purified THC is sold as a certified raw ingredient or used in co-branded dispensary products,” said John Poss, Chairman and CEO of the company.